The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain
Keywords:
Liposomal amphotericin-B
Fungal-infections
Aspergillosis
Epidemiology
Secure
Life
Citation:
Azanza-Perea, J. (José Ramón); Grau, S.; Vazquez, L.; et al. "The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain". Mycoses. 64 (1), 2021, 66 - 77
Statistics and impact
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.